The future of venous anastomosis during vascular graft implantation using an endovascular approach.
The future of venous anastomosis during vascular graft implantation using an endovascular approach.
Phraxis is a forward-thinking medical device company, based out of Minneapolis, MN currently developing a novel endovascular coaxial connector for venous anastomosis.
The investigational EndoForce™ is a patented endovascular implant for coaxial, endovascular anastomosis of a vein to an arteriovenous graft for hemodialysis.
The EndoForce™ was designed to provide an alternative, less traumatic endovascular venous anastomosis that may ameliorate the clinical challenges associated with a sutured anastomosis.
Our experienced leadership team excels in general management, product development, and clinical and regulatory affairs. With a proven track record of guiding medical device companies to successful commercialization, we are committed to making a lasting impact in healthcare.
The EndoForce™ Venous Anastomotic Connector was developed to provide an endovascular method for the attachment of an arteriovenous graft to a vein in the upper extremity to enable hemodialysis for patients with end stage renal disease.
Minneapolis, MN information@phraxis.com
The EndoForce™ is an investigational device limited by federal (United States) law to investigational use.
Copyright © 2023 Phraxis - All Rights Reserved.